COX-2 in play at the AHA and the FDA
COX-2 in play at the AHA and the FDA
复制标题
DOI：
10.1016/j.tips.2007.05.007
复制
发表时间：
2007-07-01
影响因子：
13.8
通讯作者：
FitzGerald, Garret A.
中科院分区：
文献类型：
--
作者：
FitzGerald, Garret A.
环氧化酶（考克斯）-2的抑制可使服用非甾体类抗炎药（NSAID）的患者发生心血管事件的风险很小，但绝对如此。这种风险已通过选择性作用于考克斯-2的NSAID的安慰剂对照试验确定;传统NSAID在心血管风险方面似乎是异质性的。美国心脏协会（AHA）提出了一种“分步护理”的方法来使用NSAID的心血管疾病患者，而美国食品和药物管理局（FDA）未能批准考克斯-2-选择性NSAID依托考昔。在这篇文章中，AHA和FDA的这些行动是根据目前的知识来解释的，提示可能要解决的科学问题的制定。
The inhibition of cyclooxygenase (COX)-2 confers a small but absolute risk of cardiovascular events on patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). This risk has been established by placebo-controlled trials of NSAIDs selective for COX-2; traditional NSAIDs seem to be heterogeneous with respect to cardiovascular risk. The American Heart Association (AHA) has proposed a 'stepped-care' approach to the use of NSAIDs in patients with cardiovascular disease, whereas the Food and Drug Administration (FDA) has failed to approve the COX-2-selective NSAID etoricoxib. In this article, these actions of the AHA and the FDA are interpreted in the light of current knowledge, prompting the formulation of scientific questions that might be addressed.